COSM Earnings Date: Nov 13, 2026 (Estimated) — Cosmos Health Inc.
NASDAQ · Healthcare · Medical Distribution
Updated
When is COSM's next earnings date?
Cosmos Health Inc. (COSM) is expected to report earnings on Friday, November 13, 2026; the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.04 on revenue of $17.3M.
How did COSM do in its last earnings report?
In its most recent report on Aug 19, 2026, Cosmos Health Inc. posted EPS of -$0.10 versus the -$0.10 estimate, an in-line result. Revenue was $19.3M against a $19.0M estimate. The stock's 1-day post-earnings move was +2.9%.
How much does COSM stock move after earnings?
COSM beat EPS estimates in 1 of its last 6 reported quarters. Over the last 8 reports the stock moved an average of 6.2% (up or down) in the day after earnings.
About Cosmos Health Inc.
Cosmos Health Inc. functions as a vertically integrated pharmaceutical firm, providing its own line of branded and generic medicines, nutraceuticals, non-prescription drugs, healthcare and infant products, medical devices, and various other goods. These are distributed via its established channels and an e-commerce marketplace. The company actively seeks, obtains, develops, and commercializes solutions designed to improve patients' well-being and health outcomes. Supporting these operations, it maintains distribution centers in both Greece and the United Kingdom, alongside a dedicated warehousing facility. Its clientele includes wholesale pharmaceutical distributors and independent retail pharmacies. Cosmos Health Inc. was established in 2009 and has its headquarters in Chicago, Illinois.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-19 | -0.10 | -0.10 | +0.00% | $19.3M | ➖ Inline | +2.90% | -0.58% | +43.42% | |
| 2026-08-18 | Q2 2026 | 0.01 | -0.10 | -1100.00% | $19.0M | ❌ Miss | -6.58% | -0.58% | +43.42% |
| 2026-05-21 | Q1 2026 | -0.01 | -0.06 | -500.00% | $17.9M | ❌ Miss | -10.20% | -8.79% | -25.71% |
| 2026-04-15 | Q4 2025 | -0.05 | -0.04 | +20.00% | $19.7M | ✅ Beat | +16.92% | +4.40% | -9.31% |
| 2025-11-17 | Q3 2025 | — | -0.02 | — | $17.1M | — | -3.07% | -6.18% | -30.50% |
| 2025-08-18 | Q2 2025 | — | -0.10 | — | $14.7M | — | -5.30% | -6.09% | +5.70% |
| 2025-04-16 | Q4 2024 | -0.11 | -0.45 | -309.09% | $14.2M | ❌ Miss | -0.83% | +15.01% | +28.23% |
| 2024-11-14 | Q3 2024 | -0.11 | -0.45 | -309.09% | $12.4M | ❌ Miss | -3.60% | +16.30% | +7.12% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q1 FY26 · $17.9M total
| Segment | Share | Revenue | YoY | Q4 FY23 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Wholesale | 94.2% | $16.9M | — | — | — | $26.0M | $14.6M |
| Nutraceuticals and Pharmaceuticals | 4.4% | $796K | -15.2% | — | $939K | $1.6M | $2.1M |
| Pharma manufacturing | 1.3% | $238K | -11.3% | $254K | $269K | $801K | $413K |
By region
Q3 FY23 · $278K total
| Segment | Share | Revenue | YoY | Q2 FY18 | Q3 FY18 | Q2 FY23 | Q3 FY23 |
|---|---|---|---|---|---|---|---|
| UK | 68.7% | $191K | — | $6.2M | $8.2M | $746K | $191K |
| Cyprus | 26.2% | $73K | — | — | — | $35K | $73K |
| Croatia | 5.1% | $14K | — | — | — | — | $14K |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.